Chennai Covishield volunteer to move court against Serum Institute

Serum Institute of India said the volunteer was "falsely laying the blame for his medical problems on the vaccine trial"

Serum institute, coronavirus, vaccine, pharma, drugs
SII produces 1.5 billion annual dosages for polio, diphtheria, tetanus, BCG among other vaccines
T E Narasimhan Chennai
3 min read Last Updated : Dec 10 2020 | 10:25 PM IST
The 40-year-old Chennai volunteer, who had earlier sent a legal notice to the Pune-based Serum Institute of India (SII) against its Covishield vaccine trial, has decided to move court.

Earlier, he had sent a legal notice seeking ~5 crore in damages, alleging he had developed severe neurological complications and impaired cognitive functions after he took the first jab, for which SII is seeking marketing authorisation from the Indian regulator.

R Rajaram, one of the advocates for the volunteer's family, told Business Standard that they are preparing the writ petition and will be moving court in the next few days. They have asked the Centre and the Indian Council of Medical Research (ICMR) to not give SII approval to test, manufacture, and distribute the vaccine.

"..he (the volunteer) was healthy till he got the first dose. We want SII to prove there is absolutely no correlation with the vaccine trial and his medical condition," said Rajaram, adding, SII’s lawyers wanted his client to withdraw the legal notice.

“Our client is suffering due to the ill-effects of the vaccine. He has to be compensated for his suffering. Further, a detailed investigation has to be done on the Covishield vaccine and its side-effects,” said N G R Prasad, advocate, Row & Reddy.

Meanwhile, the volunteer has asked Sri Ramachandra Institute of Higher Education and Research and the hospital to return his medical records.

According to ICMR norms, a patient is entitled to copies of all his medical records.

“The hospital has called the volunteer for review. We have asked the hospital to specify the purpose. Based on its reply, the volunteer will attend the review,” added Rajaram.

He claims the volunteer's condition has not improved significantly and he’s still unable to focus.

The volunteer is a Chennai-based business consultant. He volunteered for the third phase of human trials at Sri Ramachandra Institute for testing the Covid-19 vaccine developed by the University of Oxford. He had signed the consent form on September 29 after the test for antibodies against Covid-19 was negative. The Covishield study vaccine was administered to him on October 1, according to the legal notice sent by the volunteer to SII and others.

Ten days after the jab, there was no serious adverse effect, but on October 11, the volunteer woke up with a debilitating headache and nausea.

There was complete behavioural change in him. He was not aware of his surroundings. He showed irritation towards light and sound, and resisted any effort to wake up, said the legal notice.

The notice was sent to SII, ICMR, AstraZeneca UK, Drugs Controller General of India, Andrew Pollard, director, Oxford Vaccine Group, Jenner Institute, University of Oxford, and Vice-Chancellor of Sri Ramachandra Institute of Higher Education and Research.

On its part, SII said it would file a countersuit claiming damages of over ~100 crore, which the volunteer's wife had termed “shocking, intimidating, and childish".

Describing the allegations in the legal notice sent by the family of the volunteer as "malicious and misconceived", SII said the volunteer was "falsely laying the blame for his medical problems on the vaccine trial".

One subscription. Two world-class reads.

Already subscribed? Log in

Subscribe to read the full story →
*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

Topics :CoronavirusCoronavirus VaccineSerum Institute of IndiaChennai

Next Story